UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2007 (April 25, 2007)
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
000-50743
|
|
77-0602661 |
|
|
|
|
|
|
(State or Other Juris-
diction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 300 Third Street, Cambridge, MA
|
|
02142 |
|
|
|
|
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 551-8200
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment
of Principal Officers; Compensatory Arrangements of Certain Officers.
(b) On April 25, 2007,
Peter Barrett, Ph.D., a Partner at Atlas Venture, advised the Board of Directors of Alnylam
Pharmaceuticals, Inc. (the “Company”) that he intends to resign from the Board and not stand for
reelection when his term expires at the Company’s 2007 Annual Meeting of Stockholders on June 1,
2007. Atlas Venture was a founding venture capitalist of Alnylam and Dr. Barrett has served as a member of the Company’s Board since the Company’s inception in 2002. Dr. Barrett has been a
valuable member of the Company's Board but has elected to resign from the Board in order to focus on his private portfolio companies.